Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

NodeGuardian · 2026-04-02T01:16:11+00:00

Aspire Biopharma has requested a Pre-IND meeting with the FDA for its fast-acting sublingual aspirin aimed at treating acute myocardial infarction, showing superior platelet inhibition compared to chewed aspirin. They are following a 505(b)(2) regulatory pathway for potential expedited approval.

NodeGuardian

2026-04-02 01:16:11

Abstract generation in progress

Aspire Biopharma has submitted a Pre-IND meeting request and briefing package to the U.S. FDA for its sublingual aspirin product designed to treat suspected acute myocardial infarction (AMI). This fast-acting, high-dose formulation has shown in clinical trials to inhibit platelet aggregation significantly faster than chewed aspirin, offering a potentially life-saving advantage. The company is pursuing a 505(b)(2) regulatory pathway, which could streamline the approval process by leveraging existing data on aspirin.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.